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Background: Patients undergoing catheter ablation for atrial fibrillation (AF) are at increased thrombembolic risk and require anticoagulation. 
Dabigatran (D), an oral direct thrombin inhibitor, has recently been approved for stroke risk reduction. Experiences with D after AF ablation are 
limited to one small study with a short follow-up of 30 days. Thus, we aimed to assess the longer-term safety and efficacy of D in this population. 
Methods: From July 2010 until September 2011, patients were prospectively included. Dabigatran was started the same evening depending on 
the status of femoral puncture sites, otherwise low-molecular weight heparin was given until D was started. Patients with renal insufficiency were 
excluded. Clinical follow-up was performed at 3,6 and 12 months with continuation of anticoagulation for at least 3 months depending on results of 
serial 7-day Holter ECGs and on patient´s CHA2Ds2-VASc-Score. Clinical outcome (stroke, thrombembolic events, major bleeding), adverse effects 
and anticoagulation status were assessed.
Results: 89 patients with AF [63+/-8years, 78% male, 57% paroxysmal AF, left atrial diameter (PLAX) 42+/-6mm] were treated with D twice 
daily (110mg in 78%, 150mg in 22% of patients). Thromboembolic risk [CHA2Ds2-VASc-Score 2 (IQR 0;5)] was intermediate and bleeding risk 
[HASBLED Score 1 (IQR 0;3)] low. Arrhythmia recurrences were noted in 34%, 25% and 21% of patients at 3, 6 and 12 months respectively. During 
follow-up electrical cardioversion for arrhythmia recurrence was performed in 9 patients. Only 1 patient underwent transesophageal echo as he had 
discontinued D. During a follow-up of 274 (IQR 59;497) days no stroke, systemic embolism, no minor or major hemorrhage could be observed. 
Conclusions: An anticoagulation approach with D proved safe and effective in preventing thromboembolic events at mid-term follow-up and was 
associated with high patient acceptance. Due to its predictable dose-response relationship without the need of “bridging” and laboratory monitoring 
this regime presents an attractive alternative to the conventional approach with warfarin.
